Skip to main content
Top
Published in: BMC Nephrology 1/2015

Open Access 01-12-2015 | Research article

Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort

Authors: Xia Cao, Jiansong Zhou, Hong Yuan, Liuxin Wu, Zhiheng Chen

Published in: BMC Nephrology | Issue 1/2015

Login to get access

Abstract

Background

It is widely accepted that metabolic syndrome is associated with an increased risk of chronic kidney disease (CKD). To investigate whether coexisting metabolic syndrome is a necessary condition for CKD in overweight and obese.

Methods

A cohort study of 6852 Chinese individuals from August 2007 to December 2012. Examinations included a questionnaire, physical measurements, and blood sampling. Hazard ratios for incident CKD were estimated according to combinations of BMI category and absence or presence of metabolic syndrome.

Results

For CKD, multivariable adjusted hazard ratios vs. normal weight individuals without metabolic syndrome were 1.31 (95 % CI, 0.89–1.92) in overweight and 2.39 (95 % CI, 1.27–4.52) in obese without metabolic syndrome and 1.54 (95 % CI, 1.18–3.95) in normal weight, 2.06 (95 % CI, 1.27–3.36) in overweight, and 2.77 (95 % CI, 1.42–4.31) in obese with metabolic syndrome. There were no interactions between BMI and absence or presence of metabolic syndrome on risk of CKD when BMI was categorized (normal weight, overweight, obese) (P = 0.17). Among individuals both with and without metabolic syndrome there were increasing cumulative incidences of CKD from normal weight through overweight to obese individuals (log-rank trend P = 0.04 to P < 0.001). Although the multivariable adjusted hazard ratio for CKD in individuals with vs. without metabolic syndrome was 1.82 (95 % CI, 1.20–2.78) within overweight and obese individuals (log-rank P = 0.005), only 26.1 % of the increased risk observed for BMI is explained by metabolic syndrome.

Conclusions

These findings suggest overweight and obesity are risk factors for CKD regardless of the presence or absence of metabolic syndrome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Doyon A, Schaefer F. The prodromal phase of obesity-related chronic kidney disease: early alterations in cardiovascular and renal function in obese children and adolescents. Nephrol Dialysis Transplantation Off Publ European Dialysis Transplant Assoc European Renal Assoc. 2013;28 Suppl 4:iv50–7. Doyon A, Schaefer F. The prodromal phase of obesity-related chronic kidney disease: early alterations in cardiovascular and renal function in obese children and adolescents. Nephrol Dialysis Transplantation Off Publ European Dialysis Transplant Assoc European Renal Assoc. 2013;28 Suppl 4:iv50–7.
2.
go back to reference Spoto B, Mattace-Raso F, Sijbrands E, Mallamaci F, Leonardis D, Aucella F, et al. The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity. Nephrol Dialysis Transplantation Off Publ European Dialysis Transplant Assoc European Renal Assoc. 2012;27(27 Suppl 4):iv58–62. Spoto B, Mattace-Raso F, Sijbrands E, Mallamaci F, Leonardis D, Aucella F, et al. The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity. Nephrol Dialysis Transplantation Off Publ European Dialysis Transplant Assoc European Renal Assoc. 2012;27(27 Suppl 4):iv58–62.
3.
go back to reference Kopple JD, Feroze U. The effect of obesity on chronic kidney disease. J Renal Nutrition Off J Council Renal Nutrition National Kidney Foundation. 2011;21(1):66–71.CrossRef Kopple JD, Feroze U. The effect of obesity on chronic kidney disease. J Renal Nutrition Off J Council Renal Nutrition National Kidney Foundation. 2011;21(1):66–71.CrossRef
4.
go back to reference Zoccali C. Overweight, obesity and metabolic alterations in chronic kidney disease. Prilozi/Makedonska akademija na naukite i umetnostite, Oddelenie za bioloski i medicinski nauki = Contributions/Macedonian Academy of Scie Arts, Section Biological Medical Sci. 2009;30(2):17–31. Zoccali C. Overweight, obesity and metabolic alterations in chronic kidney disease. Prilozi/Makedonska akademija na naukite i umetnostite, Oddelenie za bioloski i medicinski nauki = Contributions/Macedonian Academy of Scie Arts, Section Biological Medical Sci. 2009;30(2):17–31.
5.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–5.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–5.CrossRefPubMed
6.
go back to reference Burton JO, Gray LJ, Webb DR, Davies MJ, Khunti K, Crasto W, et al. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol Dialysis Transplantation Off publ European Dialysis Transplant Assoc European Renal Assoc. 2012;27(5):1860–6.CrossRef Burton JO, Gray LJ, Webb DR, Davies MJ, Khunti K, Crasto W, et al. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol Dialysis Transplantation Off publ European Dialysis Transplant Assoc European Renal Assoc. 2012;27(5):1860–6.CrossRef
7.
go back to reference Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntner P, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dialysis Transplantation Off Publ European Dialysis Transplant Assoc European Renal Assoc. 2007;22(4):1100–6.CrossRef Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntner P, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dialysis Transplantation Off Publ European Dialysis Transplant Assoc European Renal Assoc. 2007;22(4):1100–6.CrossRef
8.
go back to reference Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol JASN. 2005;16(7):2134–40.CrossRefPubMed Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol JASN. 2005;16(7):2134–40.CrossRefPubMed
9.
go back to reference Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–8.CrossRefPubMed Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–8.CrossRefPubMed
10.
go back to reference Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 2005;68(1):263–70.CrossRefPubMed Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 2005;68(1):263–70.CrossRefPubMed
11.
go back to reference Espinoza R, Gracida C, Cancino J, Ibarra A. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 2006;38(3):888–9.CrossRefPubMed Espinoza R, Gracida C, Cancino J, Ibarra A. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 2006;38(3):888–9.CrossRefPubMed
12.
go back to reference Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88(5 Pt 1):2460–70.CrossRefPubMed Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88(5 Pt 1):2460–70.CrossRefPubMed
13.
go back to reference Qin Y, Melse-Boonstra A, Pan X, Yuan B, Dai Y, Zhao J, et al. Anemia in relation to body mass index and waist circumference among Chinese women. Nutr J. 2013;12:10.CrossRefPubMedPubMedCentral Qin Y, Melse-Boonstra A, Pan X, Yuan B, Dai Y, Zhao J, et al. Anemia in relation to body mass index and waist circumference among Chinese women. Nutr J. 2013;12:10.CrossRefPubMedPubMedCentral
14.
go back to reference Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol JASN. 2006;17(10):2937–44.CrossRefPubMed Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol JASN. 2006;17(10):2937–44.CrossRefPubMed
15.
go back to reference Kashif W, Siddiqi N, Dincer AP, Dincer HE, Hirsch S. Proteinuria: how to evaluate an important finding. Cleve Clin J Med. 2003;70(6):535. 537, 541–534, 546–537.CrossRefPubMed Kashif W, Siddiqi N, Dincer AP, Dincer HE, Hirsch S. Proteinuria: how to evaluate an important finding. Cleve Clin J Med. 2003;70(6):535. 537, 541–534, 546–537.CrossRefPubMed
16.
go back to reference Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997;16(13):1515–27.CrossRefPubMed Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997;16(13):1515–27.CrossRefPubMed
17.
go back to reference Zoccali C, Mallamaci F. Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? J Renal Nutrition Off J Council Renal Nutrition National Kidney Foundation. 2011;21(1):87–91.CrossRef Zoccali C, Mallamaci F. Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? J Renal Nutrition Off J Council Renal Nutrition National Kidney Foundation. 2011;21(1):87–91.CrossRef
18.
go back to reference Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association between body mass index and CKD in apparently healthy men. Am Jof Kidney Diseases Off J National Kidney Foundation. 2005;46(5):871–80.CrossRef Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association between body mass index and CKD in apparently healthy men. Am Jof Kidney Diseases Off J National Kidney Foundation. 2005;46(5):871–80.CrossRef
19.
go back to reference Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol CJASN. 2011;6(10):2364–73.CrossRefPubMed Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol CJASN. 2011;6(10):2364–73.CrossRefPubMed
20.
go back to reference Chang Y, Ryu S, Suh BS, Yun KE, Kim CW, Cho SI. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes (Lond). 2012;36(9):1187–94.CrossRef Chang Y, Ryu S, Suh BS, Yun KE, Kim CW, Cho SI. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes (Lond). 2012;36(9):1187–94.CrossRef
21.
go back to reference Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Soderberg S, Alberti KG, et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring). 2008;16(12):2707–16.CrossRef Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Soderberg S, Alberti KG, et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring). 2008;16(12):2707–16.CrossRef
22.
go back to reference Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertension Res Off J Japanese Soc Hypertension. 2010;33(5):386–93.CrossRef Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertension Res Off J Japanese Soc Hypertension. 2010;33(5):386–93.CrossRef
23.
go back to reference Arnlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care. 2011;34(1):61–5.CrossRefPubMed Arnlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care. 2011;34(1):61–5.CrossRefPubMed
24.
go back to reference Palaniappan LP, Wong EC, Shin JJ, Fortmann SP, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. Int J Obes (Lond). 2011;35(3):393–400.CrossRef Palaniappan LP, Wong EC, Shin JJ, Fortmann SP, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. Int J Obes (Lond). 2011;35(3):393–400.CrossRef
25.
go back to reference Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J kidney Diseases Off J National Kidney Foundation. 2008;52(1):39–48.CrossRef Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J kidney Diseases Off J National Kidney Foundation. 2008;52(1):39–48.CrossRef
26.
go back to reference Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the hypertension detection and follow-Up program. Am J Kidney Diseasese Off J National Kidney Foundation. 2005;46(4):587–94.CrossRef Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the hypertension detection and follow-Up program. Am J Kidney Diseasese Off J National Kidney Foundation. 2005;46(4):587–94.CrossRef
27.
go back to reference Sarafidis PA, Lasaridis AN. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome? J Cardiometab Syndr. 2008;3(3):183–7.CrossRefPubMed Sarafidis PA, Lasaridis AN. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome? J Cardiometab Syndr. 2008;3(3):183–7.CrossRefPubMed
28.
go back to reference Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, et al. ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol. 2011;22(6):1122–8.CrossRefPubMedPubMedCentral Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, et al. ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol. 2011;22(6):1122–8.CrossRefPubMedPubMedCentral
29.
go back to reference Blum CA, Ellis JL, Loh C, Ng PY, Perni RB, Stein RL. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem. 2011;54(2):417–32.CrossRefPubMed Blum CA, Ellis JL, Loh C, Ng PY, Perni RB, Stein RL. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem. 2011;54(2):417–32.CrossRefPubMed
30.
go back to reference He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010;120(4):1056–68.CrossRefPubMedPubMedCentral He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010;120(4):1056–68.CrossRefPubMedPubMedCentral
31.
go back to reference Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565–74.CrossRefPubMedPubMedCentral Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565–74.CrossRefPubMedPubMedCentral
32.
go back to reference Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16(7):2119–26.CrossRefPubMed Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16(7):2119–26.CrossRefPubMed
33.
go back to reference Serpa Neto A, Bianco Rossi FM, Dal Moro Amarante R, Alves Buriti N, Cunha Barbosa Saheb G, et al. Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J Nephrol. 2009;22(5):637–46.PubMed Serpa Neto A, Bianco Rossi FM, Dal Moro Amarante R, Alves Buriti N, Cunha Barbosa Saheb G, et al. Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J Nephrol. 2009;22(5):637–46.PubMed
Metadata
Title
Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort
Authors
Xia Cao
Jiansong Zhou
Hong Yuan
Liuxin Wu
Zhiheng Chen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2015
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-015-0083-8

Other articles of this Issue 1/2015

BMC Nephrology 1/2015 Go to the issue